Skip to main content

Table 8 Lumpectomy and mastectomy frequencies in the Safety and Efficacy populations after study treatment (number of patients and percentage of respective analysis subset)

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

 

Safety

ITT

PP

 

N = 32

= 4 months (N = 14)

> 4 months (N = 15)

= 4 months (N = 14)

> 4 months (N = 11)

 

n (%)

n (%)

n (%)

n (%)

n (%)

Lumpectomy

22 (68.8%)

10 (71.4%)

12 (80.0%)

10 (71.4%)

8 (72.7%)

Mastectomy

9 (28.1%)

4 (28.6%)

3 (20.0%)

4 (28.6%)

3 (27.3%)

Missing data

1 (3.1%)

--

--

--

--

Total

32 (100.0%)

14 (100.0%)

15 (100.0%)

14 (100.0%)

11 (100.0%)